In the US, the HALT-C trial reported that the sensitivity and specificity of PIVKA-II (74% and 46%) for the detection of early HCC were higher than those of AFP (61% and 81%), but the combination had a higher sensitivity than either biomarker alone (91%), with a 74% specificity [30]. This evidence concerns the gene AFP and hepatocellular carcinoma.